Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ole Isacson, Dr.Med.Sci, M.B.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cooper O, Hallett P, Isacson O. Upstream lipid and metabolic systems are potential causes of Alzheimer's disease, Parkinson's disease and dementias. FEBS J. 2022 Sep 27. PMID: 36165619.
    Citations: 1     Fields:    
  2. Wallom KL, Fernández-Suárez ME, Priestman DA, Te Vruchte D, Huebecker M, Hallett PJ, Isacson O, Platt FM. Glycosphingolipid metabolism and its role in ageing and Parkinson's disease. Glycoconj J. 2022 02; 39(1):39-53. PMID: 34757540; PMCID: PMC8979855.
    Citations:    Fields:    Translation:HumansCells
  3. Thomas R, Moloney EB, Macbain ZK, Hallett PJ, Isacson O. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. Mol Brain. 2021 01 19; 14(1):16. PMID: 33468204.
    Citations: 3     Fields:    Translation:HumansCells
  4. Brekk OR, Honey JR, Lee S, Hallett PJ, Isacson O. Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27646-27654. PMID: 33060302.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  5. Brekk OR, Korecka JA, Crapart CC, Huebecker M, MacBain ZK, Rosenthal SA, Sena-Esteves M, Priestman DA, Platt FM, Isacson O, Hallett PJ. Upregulating ß-hexosaminidase activity in rodents prevents a-synuclein lipid associations and protects dopaminergic neurons from a-synuclein-mediated neurotoxicity. Acta Neuropathol Commun. 2020 08 06; 8(1):127. PMID: 32762772; PMCID: PMC7409708.
    Citations: 6     Fields:    Translation:AnimalsCells
  6. Isacson O. The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable. Front Neurol. 2020; 11:745. PMID: 32793108.
    Citations: 4     
  7. Thomas R, Hallett PJ, Isacson O. Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk. Int Rev Neurobiol. 2020; 154:279-302. PMID: 32739007.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  8. Korecka JA, Thomas R, Hinrich AJ, Moskites AM, Macbain ZK, Hallett PJ, Isacson O, Hastings ML. Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. Mol Ther Nucleic Acids. 2020 Sep 04; 21:623-635. PMID: 32736291.
    Citations: 10     
  9. Osborn TM, Hallett PJ, Schumacher JM, Isacson O. Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients. Front Cell Neurosci. 2020; 14:58. PMID: 32317934.
    Citations: 8     
  10. Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM. Correction to: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2020 Jan 15; 15(1):6. PMID: 31937358; PMCID: PMC6961314.
    Citations:    Fields:    
  11. Huebecker M, Moloney EB, van der Spoel AC, Priestman DA, Isacson O, Hallett PJ, Platt FM. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2019 11 08; 14(1):40. PMID: 31703585; PMCID: PMC6842240.
    Citations: 38     Fields:    Translation:HumansCells
  12. Isacson O, Brekk OR, Hallett PJ. Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. Front Neurol. 2019; 10:1053. PMID: 31649605; PMCID: PMC6794469.
    Citations: 10     
  13. Korecka JA, Thomas R, Christensen DP, Hinrich AJ, Ferrari EJ, Levy SA, Hastings ML, Hallett PJ, Isacson O. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. Hum Mol Genet. 2019 10 01; 28(19):3232-3243. PMID: 31261377; PMCID: PMC6859523.
    Citations: 17     Fields:    Translation:HumansCells
  14. Menon V, Thomas R, Elgueta C, Horl M, Osborn T, Hallett PJ, Bartos M, Isacson O, Pruszak J. Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells. Stem Cells. 2019 10; 37(10):1293-1306. PMID: 31381839; PMCID: PMC6851846.
    Citations: 2     Fields:    Translation:HumansCells
  15. Hallett PJ, Engelender S, Isacson O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. J Neuroinflammation. 2019 Jul 22; 16(1):153. PMID: 31331333; PMCID: PMC6647317.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  16. Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, Moskites A, Atkinson E, Jodelka FM, Hinrich AJ, Hastings ML, Woolf CJ, Hallett PJ, Isacson O. Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. Stem Cell Reports. 2019 01 08; 12(1):29-41. PMID: 30595548; PMCID: PMC6335600.
    Citations: 22     Fields:    Translation:HumansCells
  17. Brekk OR, Moskites A, Isacson O, Hallett PJ. Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. Sci Rep. 2018 10 12; 8(1):15207. PMID: 30315256.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  18. Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiol Dis. 2018 12; 120:1-11. PMID: 30149180; PMCID: PMC6748034.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  19. Hallett PJ, Huebecker M, Brekk OR, Moloney EB, Rocha EM, Priestman DA, Platt FM, Isacson O. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiol Aging. 2018 07; 67:189-200. PMID: 29735433; PMCID: PMC6015735.
    Citations: 37     Fields:    Translation:AnimalsCells
  20. Osborn TM, Beagan J, Isacson O. Increased motor neuron resilience by small molecule compounds that regulate IGF-II expression. Neurobiol Dis. 2018 02; 110:218-230. PMID: 29113829.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  21. Klemann CJHM, Martens GJM, Sharma M, Martens MB, Isacson O, Gasser T, Visser JE, Poelmans G. Integrated molecular landscape of Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:14. PMID: 28649614; PMCID: PMC5460267.
    Citations: 46     
  22. Engelender S, Isacson O. The Threshold Theory for Parkinson's Disease. Trends Neurosci. 2017 01; 40(1):4-14. PMID: 27894611.
    Citations: 65     Fields:    Translation:HumansAnimalsCells
  23. Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512. PMID: 27418401.
    Citations: 4     Fields:    Translation:AnimalsCells
  24. Xiong N, Li N, Martin E, Yu J, Li J, Liu J, Lee DY, Isacson O, Vance J, Qing H, Wang T, Lin Z. hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics. 2016 07; 13(3):623-34. PMID: 27137201; PMCID: PMC4965405.
    Citations: 5     Fields:    Translation:HumansCells
  25. Wang X, Li N, Xiong N, You Q, Li J, Yu J, Qing H, Wang T, Cordell HJ, Isacson O, Vance JM, Martin ER, Zhao Y, Cohen BM, Buttner EA, Lin Z. Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. Mol Neurobiol. 2017 05; 54(4):2878-2888. PMID: 27021023.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  26. Jeon J, Kim W, Jang J, Isacson O, Seo H. Gene therapy by proteasome activator, PA28?, improves motor coordination and proteasome function in Huntington's disease YAC128 mice. Neuroscience. 2016 Jun 02; 324:20-8. PMID: 26944602.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  27. Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. a-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A. 2016 Feb 16; 113(7):1931-6. PMID: 26839413; PMCID: PMC4763774.
    Citations: 167     Fields:    Translation:HumansCells
  28. Korecka JA, Levy S, Isacson O. In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells. Mol Cell Neurosci. 2016 06; 73:3-12. PMID: 26691153.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  29. Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Glucocerebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015 Oct; 82:495-503. PMID: 26392287.
    Citations: 60     Fields:    Translation:HumansAnimalsCells
  30. Smith GA, Jansson J, Rocha EM, Osborn T, Hallett PJ, Isacson O. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. Mol Neurobiol. 2016 10; 53(8):5161-77. PMID: 26399642; PMCID: PMC5012155.
    Citations: 37     Fields:    Translation:HumansCells
  31. Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, Perez-Torres E, Hallett PJ, Isacson O. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain a-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxid Redox Signal. 2015 Aug 20; 23(6):550-64. PMID: 26094487; PMCID: PMC4544823.
    Citations: 52     Fields:    Translation:AnimalsCells
  32. Isacson O. Lysosomes to combat Parkinson's disease. Nat Neurosci. 2015 Jun; 18(6):792-3. PMID: 26007211.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  33. Isacson O. Sorting the wheat from the chaff in dopamine neuron-based cell therapies. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4512-3. PMID: 25848026; PMCID: PMC4403218.
    Citations: 3     Fields:    Translation:AnimalsCells
  34. Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS One. 2015; 10(3):e0121072. PMID: 25815475.
    Citations: 35     Fields:    Translation:AnimalsCells
  35. Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, Sundberg M, Moore MA, Perez-Torres E, Brownell AL, Schumacher JM, Spealman RD, Isacson O. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015 Mar 05; 16(3):269-74. PMID: 25732245.
    Citations: 125     Fields:    Translation:HumansAnimalsCells
  36. Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, Isacson O. Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann Clin Transl Neurol. 2015 Apr; 2(4):433-8. PMID: 25909088.
    Citations: 84     Fields:    
  37. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep. 2014 Jun 26; 7(6):1755-61. PMID: 24910427.
    Citations: 59     Fields:    Translation:HumansCells
  38. McLean JR, Smith GA, Rocha EM, Osborn TM, Dib S, Hayes MA, Beagan JA, Brown TB, Lawson TF, Hallett PJ, Robertson J, Isacson O. ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. Exp Neurol. 2014 Nov; 261:217-29. PMID: 24907400.
    Citations: 5     Fields:    Translation:HumansCells
  39. McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, Isacson O. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett. 2014 Jul 25; 576:73-8. PMID: 24882721.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  40. Zhang J, Saur T, Duke AN, Grant SG, Platt DM, Rowlett JK, Isacson O, Yao WD. Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95. J Neurogenet. 2014 Mar-Jun; 28(1-2):98-111. PMID: 24702501.
    Citations: 26     Fields:    Translation:AnimalsCells
  41. Smith GA, Rocha EM, McLean JR, Hayes MA, Izen SC, Isacson O, Hallett PJ. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet. 2014 Sep 01; 23(17):4510-27. PMID: 24728190.
    Citations: 42     Fields:    Translation:AnimalsCells
  42. Sundberg M, Isacson O. Advances in stem-cell--generated transplantation therapy for Parkinson's disease. Expert Opin Biol Ther. 2014 Apr; 14(4):437-53. PMID: 24437368.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  43. Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK. Enhanced ubiquitin-dependent degradation by Nedd4 protects against a-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiol Dis. 2014 Apr; 64:79-87. PMID: 24388974; PMCID: PMC3988924.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  44. Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis. 2014 Feb; 62:381-6. PMID: 24148854; PMCID: PMC3877733.
    Citations: 125     Fields:    Translation:HumansCells
  45. Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013 Aug; 31(8):1548-62. PMID: 23666606.
    Citations: 96     Fields:    Translation:HumansAnimalsCells
  46. Olanow CW, Isacson O. Stem cells for Parkinson's disease: advancing science but protecting patients. Mov Disord. 2012 Oct; 27(12):1475-7. PMID: 23032987.
    Citations: 4     Fields:    Translation:HumansCells
  47. Wray S, Self M, Lewis PA, Taanman JW, Ryan NS, Mahoney CJ, Liang Y, Devine MJ, Sheerin UM, Houlden H, Morris HR, Healy D, Marti-Masso JF, Preza E, Barker S, Sutherland M, Corriveau RA, D'Andrea M, Schapira AH, Uitti RJ, Guttman M, Opala G, Jasinska-Myga B, Puschmann A, Nilsson C, Espay AJ, Slawek J, Gutmann L, Boeve BF, Boylan K, Stoessl AJ, Ross OA, Maragakis NJ, Van Gerpen J, Gerstenhaber M, Gwinn K, Dawson TM, Isacson O, Marder KS, Clark LN, Przedborski SE, Finkbeiner S, Rothstein JD, Wszolek ZK, Rossor MN, Hardy J. Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One. 2012; 7(8):e43099. PMID: 22952635; PMCID: PMC3428297.
    Citations: 26     Fields:    Translation:HumansCells
  48. Smith GA, Isacson O, Dunnett SB. The search for genetic mouse models of prodromal Parkinson's disease. Exp Neurol. 2012 Oct; 237(2):267-73. PMID: 22819262.
    Citations: 12     Fields:    Translation:HumansAnimals
  49. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Daley L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA, Trojanowski JQ, Lee VM, Marder K, Surmeier DJ, Wszolek ZK, Przedborski S, Krainc D, Dawson TM, Isacson O. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med. 2012 Jul 04; 4(141):141ra90. PMID: 22764206; PMCID: PMC3462009.
    Citations: 240     Fields:    Translation:HumansCells
  50. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O. a-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis. 2012 Aug; 47(2):258-67. PMID: 22549133.
    Citations: 47     Fields:    Translation:HumansAnimals
  51. Deleidi M, Isacson O. Viral and inflammatory triggers of neurodegenerative diseases. Sci Transl Med. 2012 Feb 15; 4(121):121ps3. PMID: 22344685.
    Citations: 39     Fields:    Translation:Humans
  52. Lindvall O, Barker RA, Brüstle O, Isacson O, Svendsen CN. Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell. 2012 Feb 03; 10(2):151-5. PMID: 22305565; PMCID: PMC3982832.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  53. Cooper O, Parmar M, Isacson O. Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy. Prog Brain Res. 2012; 200:265-76. PMID: 23195423.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  54. Cooper O, Hallett P, Isacson O. Using stem cells and iPS cells to discover new treatments for Parkinson's disease. Parkinsonism Relat Disord. 2012 Jan; 18 Suppl 1:S14-6. PMID: 22166414.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  55. McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci. 2012 Feb; 49(2):230-9. PMID: 22155155.
    Citations: 20